Immunohistochemical analysis in steatohepatitis: Does it have a role in diagnosis and management?

American Journal of Clinical Pathology

Volumn 123, Issue 4, 2005, Pages 491-493

  Snover, Dale ^a  

^a FAIRVIEW SOUTHDALE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; PROTEIN TYROSINE PHOSPHATASE 1B;

EDITORIAL; FATTY LIVER; HEPATITIS C; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 15744397773     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/NP7FCTC5Q9BNTY3W     Document Type: Editorial

References (15)

1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923.
2. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
3. Ishak KG, Zimmerman HJ, Ray MB. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. Alcohol Clin Exp Res. 1991;15:45-66.
4. Uchida T, Kao H, Quispe-Sjogren M, et al. Alcoholic foamy degeneration: a pattern of acute alcoholic injury of the liver. Gastroenterology. 1983;84:683-692.
5. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological seventy. Gascroenterology. 1999;116:1413-1419.
6. Jansen PLM. Nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2004;16:10794085.
7. Hubscher SG. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2004;16:1107-1115.
8. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in non-alcoholics. Gastroenterology. 1988;95:1056-1062.
9. Sanderson SO, Smyrk TC. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens. Am J Clin Pathol. 2005;123:503-509.
10. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Goscroenterology. 2003;125:1695-1704
11. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689-692.
12. Taylor R, Heine RJ, Collins J, et al. Insulin action in cirrhosis. Hepatology. 1985;5:64-71.
13. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893-894.
14. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008-1017.
15. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188-196.